However, only about 1% of the patients in phase I and II studies with pertuzumab developed skin rash greater than grade 1 which did not demonstrate the rash characteristics typical for EGFR inhibitor therapy (Agus et al, 2005a, 2005b); (S Kelsey, Genentech, personal communication). This evidence concerns the gene EGFR and Skin rash.